Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy

Basit Öğe Kaydı
dc.authoridYasemin Kemal / 0000-0002-1175-9085
dc.authorscopusidYasemin Kemal / 23479972900
dc.authorwosidYasemin Kemal / CYJ-7779-2022
dc.contributor.authorDelikgöz Soykut, Ela
dc.contributor.authorKemal, Yasemin
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorKaraoğlanoğlu, Özden
dc.contributor.authorKurt, Mümin
dc.contributor.authorAytaç Arslan, Süheyla
dc.date.accessioned2021-10-13T13:14:52Z
dc.date.available2021-10-13T13:14:52Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractIntroduction: The purpose of this retrospective study was to investigate the prognostic impact of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune-inflammation index (SII) in predicting outcomes for patients with locally advanced non-small-cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate. Methods: Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut-off values for each biomarker. The associations between biomarkers and overall survival (OS), progression-free survival (PFS), local regional recurrence-free survival (LRRFS), and also response to radiotherapy were analysed. Results: A total of 392 patients were included. Five-year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut-off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34-2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06-1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29-2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18-2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012). Conclusion: NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.en_US
dc.identifier.citationDelikgoz Soykut, E., Kemal, Y., Karacin, C., Karaoglanoglu, O., Kurt, M., & Aytac Arslan, S. (2021). Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. Journal of medical imaging and radiation oncology, 10.1111/1754-9485.13341. Advance online publication. https://doi.org/10.1111/1754-9485.13341en_US
dc.identifier.doi10.1111/1754-9485.13341en_US
dc.identifier.issn1754-9485en_US
dc.identifier.pmid34632714en_US
dc.identifier.scopus2-s2.0-85116821246en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1111/1754-9485.13341
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2148
dc.identifier.wosWOS:000705165200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKemal, Yasemin
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofJ Med Imaging Radiat Oncol.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Inflammation Biomarkersen_US
dc.subjectNon-small-cell Lung Canceren_US
dc.subjectPrognostic Factoren_US
dc.subjectRadiosensitivityen_US
dc.subjectRadiotherapyen_US
dc.titlePrognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
113.pdf
Boyut:
6.01 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu